Notes from the Field: Cluster of Parechovirus Central Nervous System Infections in Young Infants — Tennessee, 2022
Weekly / July 29, 2022 / 71(30);977–978
Lili Tao, MD, PhD1; Mary-Margaret A. Fill, MD2; Ritu Banerjee, MD, PhD3; Romney M. Humphries, PhD1 (View author affiliations)View suggested citation
Views equals page views plus PDF downloads
During April 12–May 24, 2022, 23 previously healthy infants aged 5 days–3 months were admitted to a Tennessee children’s hospital for human parechovirus (PeV) meningoencephalitis.* PeV is a nonenveloped RNA virus of the Picornaviridae family. PeV infections range from mild, self-limiting gastroenteritis to severe sepsis-like disease and central nervous system (CNS) infection, (1) and infants aged <3 months are disproportionately affected. PeV genotype 3 is responsible for the most severe cases, with a pattern of biannual cycle circulation that peaks during summer months (2,3). Although PeV infection is not a reportable disease, the Tennessee Department of Health was notified. An assessment of cases was conducted to better understand this unusually large cluster of infections.
At this children’s hospital, a lumbar puncture is performed as part of sepsis evaluation for all infants aged <1 month and for older infants when clinically indicated. Cerebrospinal fluid (CSF) testing includes a multiplex molecular panel (BioFire FilmArray Meningitis/Encephalitis Panel, bioMerieux) for all infants aged ≤3 months and for patients aged >3 months if the CSF white blood cell (WBC) count is >5 cells per high power field. For this investigation, a comprehensive review of electronic health records was conducted to assess demographic characteristics, social history, signs and symptoms at admission, laboratory test results, and treatment course of all patients in whom PeV was detected by the multiplex molecular panel during the cluster period. This study was reviewed and approved by the Vanderbilt University Medical Center Institutional Review Board and was conducted consistent with applicable federal law and CDC policy.†
Median age of the patients was 24 days; 13 (57%) were female and 10 (43%) were male (Table). Five patients were preterm (28–36 weeks’ gestation). Signs and symptoms included fever, fussiness, and poor feeding. Most patients became symptomatic in the community (22, 96%); one preterm infant became symptomatic while in the neonatal intensive care unit (NICU). One (4%) patient attended a child care facility, and 16 (70%) had siblings at home or were exposed to other children.
Leukopenia was detected in only four (17%) patients. CSF cell count was performed for 22 patients; seven (32%) specimens demonstrated an elevated WBC count, including three with probable blood contamination during collection. All but one of the infants were admitted to the hospital; four (17%) infants developed severe disease that required treatment in the NICU. Brain magnetic resonance imaging was performed in four severely ill NICU patients, which detected diffusion within the white matter consistent with typical PeV meningoencephalitis in all of these patients. Antibiotics were initially prescribed for the 23 patients but were discontinued for 13 (57%) within 24 hours of detection of PeV. The mean hospital stay was 4.5 days (range = 1–26 days). Twenty-one (91.3%) patients recovered without complications. One patient was scheduled for a 6-month follow-up for possible late onset hearing loss and hypercoagulation evaluation. One patient experienced persistent seizures and was anticipated to experience severe developmental delay.
The multiple molecular panel had been introduced at the children’s hospital in May 2018 to aid in the diagnosis of potential pathogens among patients with suspected meningitis or encephalitis. Nineteen cases were detected over 5 months in 2018, likely representing a baseline incidence of PeV CNS infections. Seven cases of PeV were detected during 2019–2021. The absence of a biennial peak in 2020 is presumably because of social isolation during the COVID-19 pandemic, suggesting that PeV transmission is closely associated with social activity. However, 29 cases were detected in 2022 at the children’s hospital, including the 23 cases described in this report that were detected within a 6-week period. This peak in infections might reflect relaxation of COVID-19 isolation measures, consistent with increased prevalence of other respiratory viruses (e.g., respiratory syncytial virus)§ (4,5). When PeV is circulating, clinicians should consider testing for PeV in young infants, including those with normal CSF parameters.¶ The rapid detection of PeV in CSF by multiplex molecular panels can limit antibiotic administration and improve patient management. Parents with young infants, especially those with infants aged <3 months, should be aware of the symptoms and visit a pediatrician if symptoms persist.
Corresponding author: Romney M. Humphries, email@example.com, 615-875-3210.
1Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee; 2Communicable and Environmental Diseases and Emergency Preparedness Division, Tennessee Department of Health; 3Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Ritu Banjeree reports grant support from the National Institute for Allergy and Infectious Diseases, National Institutes of Health for an unrelated rapid diagnostics trial. Romney M. Humphries reports grant support from bioMerieux, Momentum BioSciences, Ltd, and Specific Diagnostics; contract and grant support from Qiagen; consulting fees from bioMerieux, Merck, Pattern Bioscience, Inc., Qiagen, QPex Biopharma, Inc., Specific Diagnostics, and Torus; vice chairmanship of the Infectious Diseases Society of America Diagnostics Committee, and membership on the American Society for Microbiology Professional Practices Committee, College of American Pathologists Microbiology Committee, and Clinical and Laboratory Standards Institute Antimicrobial Susceptibility Testing subcommittee; and stock options in Accelerate Diagnostics and Specific Diagnostics. Mary-Margaret A. Fill reports sponsored travel from the Council of State and Territorial Epidemiologists to attend the 2022 conference. No other potential conflicts of interest were disclosed.
* Infants were hospitalized at the Monroe Carell Jr. Children’s Hospital, Vanderbilt University Medical Center, Nashville, Tennessee.
† 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
- Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Parechovirus infections [Section 3]. In: Red book: 2021–2024 report of the Committee on Infectious Diseases. Itasca, Il: American Academy of Pediatrics; 2021:561–2.
- Olijve L, Jennings L, Walls T. Human parechovirus: an increasingly recognized cause of sepsis-like illness in young infants. Clin Microbiol Rev 2017;31:e00047–17. PMID:29142080
- Abedi GR, Watson JT, Nix WA, Oberste MS, Gerber SI. Enterovirus and parechovirus surveillance—United States, 2014–2016. MMWR Morb Mortal Wkly Rep 2018;67:515–8. https://doi.org/10.15585/mmwr.mm6718a2 PMID:29746455
- Ujiie M, Tsuzuki S, Nakamoto T, Iwamoto N. Resurgence of respiratory syncytial virus infections during COVID-19 pandemic, Tokyo, Japan. Emerg Infect Dis 2021;27:2969–70. https://doi.org/10.3201/eid2711.211565 PMID:34388086
- Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US. JAMA Netw Open 2021;4:e2141779. https://doi.org/10.1001/jamanetworkopen.2021.41779 PMID:34913973
Suggested citation for this article: Tao L, Fill MA, Banerjee R, Humphries RM. Notes from the Field: Cluster of Parechovirus Central Nervous System Infections in Young Infants — Tennessee, 2022. MMWR Morb Mortal Wkly Rep 2022;71:977–978. DOI: http://dx.doi.org/10.15585/mmwr.mm7130a5.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.